Marksans Pharma Ltd has reported its highest-ever annual revenue, EBITDA and profit after tax for the financial year ended March 31, 2026, driven by strong product launches across key global markets and improved operational performance. The company recorded total income of approximately ₹3,033 crore during FY26, registering a year-on-year growth of 12.8 percent. EBITDA for the year stood at ₹601 crore with a margin of 20.4 percent, while profit after tax reached an all-time high of ₹420 crore. Earnings per share for the year came in at ₹9.2.
For the fourth quarter of FY26, Marksans Pharma reported total income of ₹891 crore, reflecting a growth of 23.1 percent compared to the corresponding quarter last year. EBITDA for the quarter stood at ₹195 crore with a margin of 22.8 percent, while earnings per share reached ₹3.3. Gross profit during FY26 increased 13.2 percent year-on-year to ₹1,674 crore, supported by a gross margin of 56.7 percent. In Q4FY26, gross profit stood at ₹466 crore with a gross margin of 54.4 percent.
Commenting on the performance, Mark Saldanha said FY26 marked a milestone year for the company as it successfully delivered on its financial guidance while achieving record revenue and profitability. He noted that growth was supported by a series of product launches across international markets, including expansion of the company’s prescription-branded portfolio in Australia. The UK business also delivered a strong recovery during the fourth quarter, recording its highest-ever quarterly revenue performance.
Marksans Pharma strengthened its presence in the United States market through the launch of 112 new stock-keeping units during the year. The company also expanded its international footprint by entering new markets including Germany, Canada and Ireland. The company’s US and North America formulations business generated revenues of ₹406 crore in the fourth quarter and ₹1,533 crore during FY26. Revenue from Rest of the World (RoW) markets stood at ₹19 crore in Q4FY26 and ₹99 crore for the full year. The company stated that geopolitical disruptions and logistics-related challenges affected order fulfilment in certain overseas markets, with some deliveries deferred to future quarters.
Marksans Pharma ended the financial year with a cash balance of approximately ₹990 crore, continuing its net cash-positive position. Cash generated from operations stood at ₹458 crore during FY26, while net capital expenditure for the year was ₹131 crore. Headquartered in Mumbai, Marksans Pharma operates across global generic pharmaceutical markets with manufacturing facilities approved by leading regulatory authorities including the USFDA, UKMHRA and Australia’s TGA.
